Samsung Bioepis’ Ontruzant Hits Britain
SEOUL, Mar. 9 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Friday its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator. Global health care company MSD has begun distributing the biosimilar that references Switzerland-based Roche Holding’s Herceptin, also known as Trastuzumab, in the country, Samsung [...]